INDEGENE
|
INDEGENE Last 5 Year Financial Ratios History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 16.98 | 15.17 | 12.01 | 938.81 | 954.66 |
CEPS(Rs) | 20.33 | 18.59 | 14.71 | 8.88 | 10.71 |
DPS(Rs) | 2.00 | - | - | - | - |
Book NAV/Share(Rs) | 107.70 | 62.96 | 47.22 | 4,319.87 | 2,045.39 |
Tax Rate(%) | 24.59 | 26.58 | 26.69 | 28.11 | 19.78 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 18.82 | 19.52 | 17.17 | 17.24 | 23.86 |
EBIT Margin(%) | 19.77 | 19.62 | 17.10 | 13.96 | 24.67 |
Pre Tax Margin(%) | 18.99 | 17.71 | 15.74 | 13.61 | 23.95 |
PAT Margin (%) | 14.32 | 13.00 | 11.54 | 9.78 | 19.22 |
Cash Profit Margin (%) | 17.15 | 15.94 | 14.13 | 11.79 | 21.86 |
Performance Ratios | |||||
ROA(%) | 14.24 | 14.60 | 15.56 | 17.66 | 33.13 |
ROE(%) | 20.45 | 27.56 | 29.50 | 30.20 | 176.32 |
ROCE(%) | 25.24 | 30.88 | 35.20 | 41.09 | 68.54 |
Asset Turnover(x) | 0.99 | 1.12 | 1.35 | 1.81 | 1.72 |
Sales/Fixed Asset(x) | 2.72 | 2.79 | 4.06 | 7.20 | 4.71 |
Working Capital/Sales(x) | 1.44 | 2.19 | 2.40 | 2.41 | 3.72 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.37 | 0.36 | 0.25 | 0.14 | 0.21 |
Receivable days | 89.95 | 90.91 | 85.94 | 79.96 | 87.03 |
Inventory Days | - | - | - | - | - |
Payable days | - | - | - | - | - |
Valuation Parameters | |||||
PER(x) | 34.05 | - | - | - | - |
PCE(x) | 28.44 | - | - | - | - |
Price/Book(x) | 5.37 | - | - | - | - |
Yield(%) | 0.35 | - | - | - | - |
EV/Net Sales(x) | 4.75 | 0.10 | 0.15 | -0.30 | -0.12 |
EV/Core EBITDA(x) | 21.00 | 0.44 | 0.78 | -1.59 | -0.44 |
EV/EBIT(x) | 24.01 | 0.50 | 0.89 | -2.15 | -0.48 |
EV/CE(x) | 5.15 | 0.14 | 0.24 | -0.64 | -0.33 |
M Cap / Sales | 4.88 | - | - | - | - |
Growth Ratio | |||||
Net Sales Growth(%) | 9.64 | 12.29 | 38.54 | 72.27 | 50.30 |
Core EBITDA Growth(%) | 10.28 | 28.10 | 45.17 | 19.77 | 77.55 |
EBIT Growth(%) | 10.49 | 28.84 | 69.62 | -2.50 | 183.49 |
PAT Growth(%) | 20.79 | 26.53 | 63.43 | -12.31 | 277.40 |
EPS Growth(%) | 11.96 | 26.25 | -98.72 | -1.66 | 2,471.51 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | - | 0.29 | 0.38 | 0.02 | 0.08 |
Current Ratio(x) | 4.48 | 2.93 | 2.96 | 2.57 | 2.30 |
Quick Ratio(x) | 4.48 | 2.93 | 2.96 | 2.57 | 2.30 |
Interest Cover(x) | 25.51 | 10.28 | 12.60 | 38.98 | 34.27 |
Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of INDEGENE
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDEGENE | ₹13,122.7 Cr | -5.2% | -1.1% | -1.8% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹375,100.0 Cr | -3% | -6.8% | -11.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹161,698.0 Cr | -0.5% | -8.4% | 25.1% | Stock Analytics | |
CIPLA | ₹128,239.0 Cr | -0.2% | 1% | -1.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹121,216.0 Cr | -3.4% | -5.6% | 6.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹106,855.0 Cr | -1.1% | -2.9% | -9.5% | Stock Analytics |
INDEGENE Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDEGENE | -5.2% |
-1.1% |
-1.8% |
SENSEX | -1.2% |
-1.2% |
-1.7% |
You may also like the below Video Courses